Despite co-developing the first COVID-19 vaccine to be authorized in the U.S. and undergoing a transformational spinoff, Pfizer’s (NYSE: PFE) stock closed out 2020 almost exactly where it began the year.Coming into the company’s earnings announcement, investors were eager to learRead MoreMarketsMarkets Feed